New publication reviews implementation of outcomes-based managed entry agreements for two rare disease therapies

Published in PharmacoEconomics, an international team of researchers has reviewed case studies regarding the implementation of outcomes-based managed entry agreements in the EU, Canada and Australia for two therapies, both indicated for rare diseases. The publication hopes to highlight practices that could aid in the development of tools to support future implementation of such agreements, when appropriate. Outcomes-based managed entry agreements represent one method of potentially mitigating the impacts of uncertainties in the clinical evidence base, for example, relating to the long-term clinical effectiveness of innovative therapies, at the time of their pricing/reimbursement and market entry. Interest and enthusiasm for...

To view this content, please register now for access

It's completely free